SAN DIEGO, Sept. 9, 2015 /PRNewswire/ -- AnaptysBio, Inc., a biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology, today announced the filing of a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock. All shares of common stock to be sold in the offering will be offered by AnaptysBio. The number of shares to be offered and the price range for the offering have not yet been determined. AnaptysBio intends to list its common stock on the NASDAQ Global Market under the ticker symbol "ANAB."
BMO Capital Markets and Stifel are acting as joint book-running managers for the proposed offering. JMP Securities and Wedbush PacGrow are acting as co-managers.
The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained by contacting BMO Capital Markets Corp., 3 Times Square, 25th Floor, New York, NY 10036, Attention: Equity Syndicate Department, or by telephone at (800) 414-3627, or by email at email@example.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by telephone at (415) 364-2720, or by email at firstname.lastname@example.org.
A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
AnaptysBio is an antibody development company focused on novel programs in inflammation and immuno-oncology. The Company's proprietary pipeline includes ANB020, an anti-IL-33 antibody for the treatment of severe adult asthma and severe adult peanut allergy, and ANB019, an anti-IL-36 receptor antibody initially being developed for the treatment of generalized pustular psoriasis. AnaptysBio's SHM-XEL platform has pioneered the use of in vitro somatic hypermutation for antibody discovery, which is designed to replicate key features of the human immune system and overcomes limitations of prior antibody technologies. AnaptysBio has previously announced partnerships with several biopharmaceutical companies, including Celgene and TESARO.